

LIVING WITH LUPUS IN 2020

COUNTRY LEVEL DATA

Norway



DATA FOR: **Norway**

Publication: http://dx.doi.org/10.1136/lupus-2020-000469

COUNTRY:	Norway				
		DEM	10GRAPHICS:		
		5115055			5110.005
T	<u>Norway</u>	<u>EUROPE</u>	Age 25	<u>Norway</u>	<u>EUROPE</u>
Total number of responses	135	4375	Up to 25	3.7%	6.4%
			26 to 35	11.9%	17.9%
<u>Gender</u>	<u>Norway</u>	<u>EUROPE</u>	36 to 45	17.8%	27.4%
Man	1.5%	3.7%	46 to 55	40.7%	26.6%
Woman	97.0%	95.6%	56 to 65	19.3%	14.8%
Other / prefer not to answer	1.5%	0.7%	above 65	5.2%	5.1%
Total	100.0%	100.0%	NA	1.5%	1.8%
			Grand Total	100.0%	100.0%
		D	DIAGNOSIS		
Diagnosis	Norway	<u>EUROPE</u>	Time to Diagnosis	Norway	<u>EUROPE</u>
SLE	95.6%	94.4%	Within the year	19.5%	26.5%
Child onset SLE	4.4%	5.6%	1 year	13.5%	21.1%
Grand Total	100.0%	100.0%	2 years	9.8%	11.5%
			3 years	7.5%	5.7%
Prior Diagnosis received before "Lupus"	<u>Norway</u>	<u>EUROPE</u>	4 years	6.8%	4.6%
None	47.4%	53.7%	5 years	3.8%	4.4%
UCTD/MCTD	1.5%	6.7%	6 years	2.3%	2.9%
Sjogren	9.6%	4.7%	7 years	1.5%	2.7%
APS	0.7%	2.4%	8 years	1.5%	2.4%
Other Autoimmune or Rheumatic	17.0%	13.8%	9 years	7.5%	2.3%
Fibromyalgia	14.1%	5.8%	10 to 20 years	13.5%	10.4%
Psychologic or mental disorder	11.9%	8.9%	More than 20 years	12.8%	5.5%
Other prior diagnosis	13.3%	16.5%	Grand Total	100.0%	100.0%
n=	133	4,275	n=	133	4,154



DATA FOR: **Norway**

Publication: http://dx.doi.org/10.1136/lupus-2020-000469

127

n=

4024

		INADACT ON CTU	DIEC & CAREER		
		IMPACT ON STUI	JIES & CAREER		
Education level	<u>Norway</u>	<u>EUROPE</u>	Employment level	<u>Norway</u>	EUROPE
Basic	11.8%	3.7%	Employed full time	20.6%	34.6%
Secundary	45.7%	53.9%	Employed part time	21.4%	16.5%
Academic	42.5%	42.5%	Self-employed full time	0.8%	3.0%
n=	127	4,150	Self-employed part time	1.5%	2.4%
			Looking for employment	0.8%	5.1%
Economic profile	<u>Norway</u>	<u>EUROPE</u>	Stopped work for medical reason	37.4%	14.7%
No difficulties paying all bills	43.0%	46.9%	Retired	12.2%	11.6%
Occasional difficulties paying all bills.	29.6%	26.8%	Student	1.5%	4.0%
Often difficulties paying all bills	14.8%	10.4%	No paid employment / Full time home	3.8%	4.7%
Always difficulty paying all bills	5.9%	7.1%	Other / prefer not to answer	0.0%	3.5%
Did not respond	6.7%	8.9%			
n=	135	4375	n=	131	4247
IMPACT ON STUDIES	<u>Norway</u>	<u>EUROPE</u>	IMPACT ON CAREER	<u>Norway</u>	EUROPE
Chose more relevant studies	3.0%	3.1%	No impact	11.0%	32.5%
could not do what they wanted	23.5%	11.1%	Changed career/ job	16.5%	13.5%
needed special support and received it	6.8%	4.6%	moved to Flexible hours	3.9%	8.1%
needed support but did NOT receive it	9.1%	2.9%	Reduced Work Schedule	26.8%	18.5%
Overall negative effect	15.2%	13.5%	Stopped work, gets social allowances	48.8%	18.5%
Overall positive effect	1.5%	1.4%	Missed promotion opportunities	7.9%	9.5%
No impact	54.5%	69.8%	Employment was terminated	6.3%	8.4%
			Other negative impact	15.0%	20.8%
n=	132	4240	Other positive impact	1.6%	1.8%
			Overall had negative impact	81.1%	57.9%



DATA FOR: **Norway**

Publication: http://dx.doi.org/10.1136/lupus-2020-000469

		IMPACT ON SOC	IAL / FAMILY		
Chilleton	Name	FURORE	Users all things	Name	FUDORE
Civil status	<u>Norway</u>	EUROPE 4.50/	<u>Have children</u>	Norway 15 40/	EUROPE
Child/young with family	2.4%	4.5%	None	15.4%	32.8%
Single	14.2%	17.4%	One child	20.0%	23.8%
Married / with partner	72.4%	66.9%	2 or more children	62.3%	38.9%
Divorced	8.7%	9.2%	Child/young living with family	2.3%	4.5%
Widowed	2.4%	2.0%			
n=	127	4206	n=	130	4288
Would have liked more children	<u>Norway</u>	<u>EUROPE</u>	Faced Misscariages	<u>Norway</u>	<u>EUROPE</u>
A. Yes	37.1%	37.6%	A. One miscarriage	21.0%	18.4%
B. No	48.4%	37.7%	B. Some miscarriages	15.3%	8.5%
C. don't know / prefer not to answer	14.5%	24.7%	C. Many miscarriages	7.3%	2.9%
·			D. No miscarriage	56.5%	70.2%
n (women only) =	124	3,645	n (women only) =	124	3,756
Difficulty to cope with Daily activities	<u>Norway</u>	EUROPE	More or less active than others same age	Norway	EUROPE
No Problem at all 1	9.9%	16.2%	Less active due to lupus	84.7%	72.6%
2	21.4%	32.3%	Equally active	9.2%	15.6%
3	42.7%	34.3%	More active due to lupus	3.8%	3.6%
4	22.9%	15.4%	I don't know	2.3%	8.1%
Fully Unable 5	3.1%	1.8%			
n=	131	4226	n=	131	4212
Impact on Sexual/emotional life	Norway	EUROPE	Negative Impact on couple	Norway	EUROPE
Negative impact	41.2%	38.2%	It created tensions	29.9%	33.2%
Mixed Positive and negative	29.8%	36.2%	It is difficult for me	72.4%	68.4%
No significant impact	28.2%	23.9%	It is difficult for my partner	28.7%	26.7%
Positive impact	0.8%	1.6%	I am concerned for my couple	14.9%	13.2%
•			Our relationship ended	21.8%	16.6%
n=	131	4,204	n=	87	2875



DATA FOR: **Norway**

Publication: http://dx.doi.org/10.1136/lupus-2020-000469

n=

131

4197

DISEASE ACTIVITY								
			Di	SLASE ACTIVITY				
Lupus was under control past 3 mont	<u>hs</u>	<u>Norway</u>	EUROPE	Number of symptoms (list of 23)	<u>Norway</u>	<u>EUROPE</u>		
Yes		66%	72%	1	0.0%	1.6%		
No		34%	28%	2	0.8%	2.1%		
				3	2.3%	4.4%		
	n=	134	4347	4	5.3%	5.9%		
				5	3.8%	6.1%		
				6	9.2%	8.5%		
		<u>Norway</u>	EUROPE	7	6.1%	9.3%		
Average nr of symptoms (list of 23)		10.1	8.8	8	9.2%	10.4%		
	n=	131	4197	9	5.3%	10.1%		
				10	9.9%	9.3%		
				11	8.4%	8.3%		
		<u>Norway</u>	EUROPE	12	9.2%	7.0%		
Median number of symptoms		10	9	13	10.7%	5.8%		
	n=	131	4197	14	7.6%	4.4%		
				15	4.6%	2.7%		
				16	4.6%	2.1%		
				17	1.5%	1.1%		
				18	0.8%	0.4%		
				19	0.0%	0.3%		
				20	0.8%	0.0%		



DATA FOR: **Norway**

Publication: http://dx.doi.org/10.1136/lupus-2020-000469

Symptoms or Features experienced / Most bothersome

	Norway			EURO)PF
	<u>Regularly</u>	Top 3 most		<u>Regularly</u>	Top 3 most
Patient reported Symptoms or features	experience	bothersome	Patient reported Symptoms or features	experience	bothersome
A. Rash	54%	7%	A. Rash	40%	9%
B. Sun sensitivity	73%	27%	B. Sun sensitivity	69%	23%
C. Mouth ulcers	42%	0%	C. Mouth ulcers	35%	3%
D. Dryness in the mouth or eyes	68%	12%	D. Dryness in the mouth or eyes	55%	9%
E. Dryness of the skin	66%	2%	E. Dryness of the skin	57%	4%
F. Hair loss	56%	7%	F. Hair loss	53%	14%
G. Pain / swelling in joints	81%	39%	G. Pain / swelling in joints	77%	49%
H. Jaccoud (hand deformation) or tendons a	15%	2%	H. Jaccoud (hand deformation) or tendor	14%	4%
I. Muscle Pain/Weakness	80%	44%	I. Muscle Pain/Weakness	68%	33%
J. Headaches or migraine	63%	23%	J. Headaches or migraine	51%	17%
K. Fatigue and weakness	90%	62%	K. Fatigue and weakness	85%	55%
L. Flu-like symptoms/Fevers	48%	5%	L. Flu-like symptoms/Fevers	28%	4%
M. Shortness of breath	53%	5%	M. Shortness of breath	32%	6%
N. Depression or Anxiety	40%	13%	N. Depression or Anxiety	44%	17%
O. Haematologic problems incl. anemia	23%	2%	O. Haematologic problems incl. anemia	27%	4%
P. Poor circulation or Raynauds	50%	10%	P. Poor circulation or Raynauds	45%	8%
Q. Kidney problems	17%	8%	Q. Kidney problems	20%	11%
R. Chest pain	37%	5%	R. Chest pain	24%	4%
S. High Blood pressure	26%	6%	S. High Blood pressure	23%	4%
T. Stroke, mini-stroke, Blood clots	11%	5%	T. Stroke, mini-stroke, Blood clots	9%	4%
U. Osteoporosis	18%	4%	U. Osteoporosis	19%	5%
n=	135	129	n=	4375	4084



DATA FOR: **Norway**

Publication: http://dx.doi.org/10.1136/lupus-2020-000469

			MEDICA	ATION		
		<u>Norway</u>	EUROPE		<u>Norway</u>	EUROPE
Average number of medication (from	Average number of medication (from list			Median number of medication (from		
<u>of 16)</u>		5.2	5.2	<u>list of 16)</u>	5	5
	n=	130	4099	n=	130	4099
Number of medications (list of 16)		<u>Norway</u>	<u>EUROPE</u>	% using given medication type:	<u>Norway</u>	EUROPE
	1	3.1%	5.4%	Non Steroids Anti-Inflammatory	19.2%	32.9%
	2	10.0%	9.0%	Antimalarials	83.1%	75.0%
	3	11.5%	12.5%	Oral Steroids	60.8%	52.4%
	4	17.7%	14.1%	Immunosuppressants	26.9%	39.8%
	5	15.4%	14.8%	Biologics	9.2%	10.9%
	6	13.8%	13.9%	Painkillers	72.3%	50.1%
	7	12.3%	11.8%	Antidepressant	8.5%	17.0%
	8	3.8%	9.0%	Anxiolytic	12.3%	11.7%
	9	7.7%	5.1%	Anticoagulants	14.6%	16.6%
	10	2.3%	2.5%	Thyroid medication	15.4%	14.8%
	11	2.3%	1.1%	Blood circulation and heart	20.8%	23.3%
	12	0.0%	0.4%	Stomach protection	32.3%	47.0%
	13	0.0%	0.2%	Statins	5.4%	5.9%
				Calcium	46.2%	29.7%
	n=	130	4099	Vitamin D	64.6%	68.4%
				Vitamins (excl.D) / mineral complements	31.5%	25.4%



DATA FOR: **Norway**

Publication: http://dx.doi.org/10.1136/lupus-2020-000469

ACCESS / Quality of life (scale of 1 to 5)

I have appropriate access to		<u>Norway</u>	<u>EUROPE</u>	HrQoL dimensions	<u>Norway</u>	<u>EUROPE</u>		
Average scores (1 Fully d	disagree -	5 fully agree)		AVERAGE SCORES (1=FULLY ABLE, 5= FULLY UNABLE)				
Experienced lupus doctors		3.17	3.81	Mobility	2.31	2.22		
Multidisciplinary team		2.79	3.28	Self care	1.64	1.71		
Specialised nurses that know lupus		2.77	2.92	Daily Activities	2.88	2.54		
Prescribed medication		3.91	4.08	Pain or discomfort	3.34	3.14		
Affordable treatments		3.15	3.77	Anxiety or depression	2.68	2.96		
Social support and benefits		2.99	2.78	Average	2.57	2.51		
Physiotherapy, Rehab, Occupational	Thera	2.87	2.77					
Professional psychological support		2.45	2.68					
r	n min	97	3126	n min	130	4196		
n	n max	119	3842	n max	131	4240		
Worry about lupus progressing?		<u>Norway</u>	<u>EUROPE</u>					
Very Low (1-2)		4.7%	3.6%					
Low (3-4)		10.9%	9.3%					
Mid (5-6)		31.0%	24.5%					
High (7-8)		40.3%	41.0%					
Very high (9-10)		13.2%	21.6%					
	n=	129	4042					



DATA FOR: **Norway**

Publication: http://dx.doi.org/10.1136/lupus-2020-000469

Impact of lupus not being under control over past 3 months

		Norwa		ed vs 100% = FULL HEALTH/ABILITY TO PERFORM	<u>EURO</u>	<u>PE</u>
		lupus under	not under		lupus under	not under
		<u>control</u>	<u>control</u>		<u>control</u>	<u>control</u>
Mobility		72%	58%	Mobility	73%	59%
Self care		88%	77%	Self care	86%	73%
Daily Activities		57%	46%	Daily Activities	66%	51%
Pain or discomfort		44%	37%	Pain or discomfort	51%	35%
Anxiety or depression		60%	54%	Anxiety or depression	54%	44%
Average		64%	54%	Average	66%	52%
	n min	84	45	n min	3011	1179
	n max	85	46	n max	3042	1194
		<u>Norwa</u>	<u>Y</u>		EURO	<u>PE</u>
		lupus under	not under	More or less active than others of same	lupus under	not under
More or less active than others of same	age	<u>control</u>	<u>control</u>	<u>age</u>	<u>control</u>	<u>control</u>
Less active due to lupus		81.2%	91.3%	Less active due to lupus	68.6%	83.0%
Equally active		10.6%	6.5%	Equally active	18.8%	7.6%
More active due to lupus		4.7%	2.2%	More active due to lupus	4.0%	2.7%
I don't know		3.5%	0.0%	I don't know	8.7%	6.7%
	n=	85	46	n=	3018	1189
		<u>Norwa</u>	Y		EURO	<u>PE</u>
		lupus under	not under		lupus under	not under
Impact on Sexual/emotional life		<u>control</u>	<u>control</u>	Impact on Sexual/emotional life	control	<u>control</u>
Negative impact		36.5%	50.0%	Negative impact	34.0%	49.0%
Mixed + and -		32.9%	23.9%	Mixed + and -	36.4%	35.7%
No significant impact		29.4%	26.1%	No significant impact	27.8%	14.1%
Positive impact		1.2%	0.0%	Positive impact	1.8%	1.2%
	n=	85	46	n=	3018	1181



DATA FOR: **Norway**

Publication: http://dx.doi.org/10.1136/lupus-2020-000469

IMPACT OF A PROMPT DIAGNOSIS

% of Health Related QoL Maintained vs 100% = FULL HEALTH/ABILITY TO PERFORM

	<u>Norv</u>	<u>vay</u>		EURC	<u>)PE</u>
		<u>Diagnosed</u>		<u>Diagnosed</u>	<u>Diagnosed</u>
	<u>Diagnosed</u>	after more		within 2	after more
	within 2 years	than 5 years		<u>years</u>	than 5 years
Mobility	78%	60%	Mobility	75%	62%
Self care	92%	79%	Self care	86%	76%
Daily Activities	62%	45%	Daily Activities	67%	53%
Pain or discomfort	51%	35%	Pain or discomfort	52%	39%
Anxiety or depression	59%	55%	Anxiety or depression	52%	49%
Average	68%	55%	Average	66%	56%
Difference		-14%	Difference		-10%
of which - explained by age (*)		-3%	of which - explained by age		-3%
n min	41	56	n min	1926	1239
n max	42	57	n max	1951	1249
average age:	44.7	52.0		41.2	49.0


^(*) in our overall study, we found that from age 28 to age 63 HrQOL drops from 69.1% to 56.0% i.e. 3.7% per decade





DATA FOR: Norway


Publication: http://dx.doi.org/10.1136/lupus-2020-000469

DATA FOR: Norway













DATA FOR: Norway

Publication: http://dx.doi.org/10.1136/lupus-2020-000469

DATA FOR: Norway







Living with lupus in 2020 - Country level data

DATA FOR: Norway

For full text european analysis, please refer to:

Cornet A, Andersen J, Myllys K, et al. Living with systemic lupus erythematosus in 2020: a European patient survey. Lupus Science & Medicine 2021;8:e000469. doi:10.1136/lupus-2020-000469

For more informatioin, contact: secretariat@lupus-europe.org